Updated on 14 January 2014
The partnership has collateral benefits for the nation that goes beyond the advancing of development of broadly effective AIDS vaccines. Most significantly, the DBT expects that it will contribute to India's efforts to become a world leader in translational research-the science of converting promising laboratory concepts into biomedical products that can be tested in people and, ultimately, manufactured by industry.
The annual operational funding for the program as per Dr Sukhdev Sinha, advisor, DBT, is close to Rs 40 crore. The DBT has put another Rs 6 crore into various 25 projects that are into R&D of these diseases. He adds, "India holds a very unique place in the vaccine development. We know that the vaccine development success stories in India have made us to believe in wonders. Now the focus is more on few major disease areas such as HCV, HIV and TB. At the moment, along with the DBT, the DST, CSIR and other too are putting money in HIV infection research in one or the other way."